Literature DB >> 11823124

Imaging and quantitation of the hypoxic cell fraction of viable tumor in an animal model of intracerebral high grade glioma using [18F]fluoromisonidazole (FMISO).

Henri J Tochon-Danguy1, John I Sachinidis, Fiona Chan, J Gordon Chan, Catherine Hall, Lawrence Cher, Stan Stylli, John Hill, Andrew Kaye, Andrew M Scott.   

Abstract

We have demonstrated that FMISO uptake is significantly higher in tumor tissue in the C6 intracerebral glioma rat model compared to normal brain, and that there is persisting hypoxia in gliomas independent of tumor size. FMISO uptake was observed homogeneously throughout viable glioma tissue in tumor sizes ranging from 2mm to almost 1cm. Quantitation of uptake of FMISO showed a tumor/brain ratio of 1.9 and a tumor/blood ratio of 2.6 at 2 hours post injection.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11823124     DOI: 10.1016/s0969-8051(01)00298-0

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  16 in total

Review 1.  Imaging hypoxia in gliomas.

Authors:  I Mendichovszky; A Jackson
Journal:  Br J Radiol       Date:  2011-12       Impact factor: 3.039

Review 2.  Exploring the nature of atheroma and cardiovascular inflammation in vivo using positron emission tomography (PET).

Authors:  J R Buscombe
Journal:  Br J Radiol       Date:  2015-09       Impact factor: 3.039

Review 3.  Brain tumor hypoxia: tumorigenesis, angiogenesis, imaging, pseudoprogression, and as a therapeutic target.

Authors:  Randy L Jensen
Journal:  J Neurooncol       Date:  2009-04-09       Impact factor: 4.130

4.  [18F]EF3 is not superior to [18F]FMISO for PET-based hypoxia evaluation as measured in a rat rhabdomyosarcoma tumour model.

Authors:  Ludwig Dubois; Willy Landuyt; Lieselotte Cloetens; Anne Bol; Guy Bormans; Karin Haustermans; Daniel Labar; Johan Nuyts; Vincent Grégoire; Luc Mortelmans
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-08-09       Impact factor: 9.236

5.  Comparison of the biodistribution of two hypoxia markers [18F]FETNIM and [18F]FMISO in an experimental mammary carcinoma.

Authors:  Tove Grönroos; Lise Bentzen; Päivi Marjamäki; Rumi Murata; Michael R Horsman; Susanne Keiding; Olli Eskola; Merja Haaparanta; Heikki Minn; Olof Solin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-01-14       Impact factor: 9.236

6.  Complementary but distinct roles for MRI and 18F-fluoromisonidazole PET in the assessment of human glioblastomas.

Authors:  Kristin R Swanson; Gargi Chakraborty; Christina H Wang; Russell Rockne; Hana L P Harpold; Mark Muzi; Tom C H Adamsen; Kenneth A Krohn; Alexander M Spence
Journal:  J Nucl Med       Date:  2008-12-17       Impact factor: 10.057

7.  [PET-MR in patients with glioblastoma multiforme].

Authors:  B Ertl-Wagner; M Ingrisch; M Niyazi; O Schnell; N Jansen; S Förster; C la Fougère
Journal:  Radiologe       Date:  2013-08       Impact factor: 0.635

8.  Evaluation of repeated [(18)F]EF5 PET/CT scans and tumor growth rate in experimental head and neck carcinomas.

Authors:  Antti Silvoniemi; Jonna Silén; Sarita Forsback; Eliisa Löyttyniemi; Aleksi R Schrey; Olof Solin; Reidar Grénman; Heikki Minn; Tove J Grönroos
Journal:  EJNMMI Res       Date:  2014-12-16       Impact factor: 3.138

9.  Assessing Biological Response to Bevacizumab Using 18F-Fluoromisonidazole PET/MR Imaging in a Patient with Recurrent Anaplastic Astrocytoma.

Authors:  Ramon F Barajas; Miguel H Pampaloni; Jennifer L Clarke; Youngho Seo; Dragana Savic; Randall A Hawkins; Spencer C Behr; Susan M Chang; Mitchel Berger; William P Dillon; Soonmee Cha
Journal:  Case Rep Radiol       Date:  2015-02-22

10.  Evaluation of hypoxia in an experimental rat tumour model by [(18)F]fluoromisonidazole PET and immunohistochemistry.

Authors:  L Dubois; W Landuyt; K Haustermans; P Dupont; G Bormans; P Vermaelen; P Flamen; E Verbeken; L Mortelmans
Journal:  Br J Cancer       Date:  2004-11-29       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.